People who took semaglutide over a slower, more flexible schedule were significantly less likely to experience nausea and to ...

Three studies presented today at the Society of NeuroInterventional Surgery’s (SNIS) 22nd Annual Meeting discussed whether ...

UK drug chiefs have approved the use of semaglutide, the main ingredient of Ozempic and Wegovy, to prevent heart attacks and strokes in patents who are overweight. The decision comes after scientists ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Some health experts view GLP-1s as a promising option for PCOS, which lacks a standard treatment and affects millions of ...

If you’ve been taking Ozempic or Wegovy (both of which contain the active ingredient semaglutide), you might wonder, How long ...

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

Semaglutide, a popular anti-obesity drug, may come with a hidden cost: significant muscle loss, especially in women and older ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

“Weight loss quality is a new concept….The discussion no longer revolves around the lack of adequate efficacy but rather ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Pointing to Ozempic as a paradigm shift, an elite rehab center is experimenting with GLP-1s to tame many forms of addiction.